Delivering the neuropeptide Substance P to diabetic wounds in mice and rabbits reversed chronic inflammation and accelerated healing by shifting immune cells toward a repair-promoting state.
SP-deficient mice showed impaired healingMice lacking Substance P or its receptor (neurokinin-1) had significantly impaired wound healing, confirming the peptide's essential role in the healing process and explaining why diabetic skin — which has reduced SP — heals so poorly.
What the researchers found
Exogenous Substance P administration improved wound healing in diabetic mouse and rabbit models by inducing an acute inflammatory response and promoting macrophage polarization toward the M2 phenotype. Deficiency of Substance P or its receptor impaired wound healing, and diabetic skin showed reduced Substance P levels with increased degradation enzyme expression.
Critically, the study demonstrated a dual problem in diabetic skin: Substance P gene expression was decreased while neutral endopeptidase (the enzyme that degrades SP) was increased at both gene and protein levels. This creates a Substance P deficit that locks diabetic wounds into persistent, non-healing inflammation rather than the normal acute-to-proliferative healing sequence.
Why it matters
Diabetic foot ulcers affect millions of people worldwide and are a leading cause of non-traumatic limb amputation. Current treatments are often inadequate because they don't address the underlying inflammatory dysfunction. This research identifies a specific molecular mechanism — Substance P depletion — driving chronic wound inflammation in diabetes, and demonstrates that replacing this peptide can restore normal healing. This could lead to topical peptide therapies for diabetic wounds.
How the study worked
Researchers used multiple animal models: diabetic mice and rabbits received exogenous Substance P treatment on skin wounds, while genetically modified mice lacking either Substance P or its receptor (neurokinin-1 receptor) were used to confirm the peptide's role in healing. The team measured SP gene expression, neutral endopeptidase levels, inflammatory markers, and macrophage phenotype (M1 vs. M2 polarization) throughout the wound healing process.
What this study cannot tell us
This study was conducted entirely in animal models (mice and rabbits), which heal differently from humans — particularly in skin structure and immune response. Specific dosing, delivery methods, and long-term safety of Substance P treatment were not detailed in the abstract. The study also did not examine whether Substance P treatment could work in established chronic wounds versus newly created experimental wounds.
How to read the evidence
This is a preclinical animal study using multiple models (diabetic mice, rabbits, and knockout mice), which provides strong mechanistic evidence but has not yet been validated in human clinical trials. The use of both gain-of-function (SP treatment) and loss-of-function (knockout) approaches strengthens the findings.
When this study was published
Published in 2015, this study is over a decade old but remains relevant as peptide-based wound therapies continue to be an active area of research. The mechanisms described here have been further explored in subsequent studies on neuropeptide roles in tissue repair.
The bigger picture
This study contributes to a growing understanding that neuropeptides play critical roles in wound healing beyond their traditional nervous system functions. The finding that diabetic skin has a specific Substance P deficit adds to the evidence that diabetes disrupts the neuro-immune crosstalk necessary for tissue repair. It also supports the broader concept of peptide-based wound therapeutics as an alternative to growth factor therapies that have shown limited clinical success.
Questions still open
- Could topical Substance P formulations be developed for clinical use in human diabetic foot ulcers?
- Would inhibiting neutral endopeptidase (the enzyme that degrades Substance P) be an alternative therapeutic strategy to restore SP levels in diabetic skin?
- Does the Substance P deficit in diabetic skin also contribute to other complications like diabetic neuropathy?
Common questions
What is Substance P and what does it normally do in wound healing?
Why do diabetic wounds heal so poorly?
Read the original research
Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype.
The American journal of pathology, 185(6), 1638-48
Citation
Leal, Ermelindo C; Carvalho, Eugénia; Tellechea, Ana; Kafanas, Antonios; Tecilazich, Francesco; Kearney, Cathal; Kuchibhotla, Sarada; Auster, Michael E; Kokkotou, Efi; Mooney, David J; LoGerfo, Frank W; Pradhan-Nabzdyk, Leena; Veves, Aristidis. (2015). Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype.. The American journal of pathology, 185(6), 1638-48. https://doi.org/10.1016/j.ajpath.2015.02.011